Prostate Implant Program
Director: Richard E. Peschel, MD, PhD
The Prostate implant program at Yale-New Haven Hospital began in 1974 with the older supra-pubic prostate implant technique. The newer and more precise ultrasound guided transperineal prostate implant (IMP) program was introduced at Yale-New Haven Hospital in 1992. With over 30 years of experience using implant therapy for prostate cancer, Yale-New Haven Hospital has the longest continuous experience with prostate implant technology in the state of Connecticut. Our IMP results are excellent and equivalent to all other national cancer centers of excellence. For early prostate cancer patients in the most favorable group (PSA < 10, Gleason score < 7), the 5-year and 10-year cure rates are over 93%. Our IMP results have been published in numerous national and international cancer journals [1,2}.
In addition to the high quality of patient care, our prostate cancer research group has contributed in significant ways to a better understanding of the fundamental radiobiology of prostate implant therapy and to a significant reduction in the complication rates [2,3]. In terms of documented high quality patient care and research programs, Yale-New Haven Hospital is a true national leader in prostate implants.
References:
- Peschel RE, Colberg JW: Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer. The Lancet Oncology 4: 233,2003.
- Peschel RE, Colberg JW, Chen Z, Nath R, Wilson LD: Iodine-125 versus palladium-103 implants: Clinical outcomes and complications. The Cancer Journal 10: 170, 2004.
- Peschel RE, Chen Z, Roberts K, Nath R: Long term complications with prostate implants: Iodine-125 versus Palladium-103. Radiation Oncology Investigations: Clinical and Basic Research 7: 278, 1999.
